A Gynecologic Oncology Group phase II study of amonafide (NSC 308847) in epithelial ovarian cancer.
In this study, 19 evaluable patients with epithelial ovarian cancer were treated with amonafide 300 mg/m2 over an hour for 5 consecutive days every 3 weeks. One partial response (5%) was seen. Hematologic toxicity was substantial with grade 3 or 4 toxicity occurring as follows: leukopenia, 10 patients (45%); thrombocytopenia, 6 patients (27%); granulocytopenia, 8 patients (36%). No other unusual or severe toxicity occurred. In view of the low response rate and high toxicity, amonafide does not warrant further investigation in epithelial ovarian cancer.
Asbury
R F
RF
Department of Oncology, University of Rochester School of Medicine, New York.
Blessing
J A
JA
Look
K Y
KY
Clarke-Pearson
D
D
Homesley
H D
HD
D000225:Adenine; D000328:Adult; D000368:Aged; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002277:Carcinoma / Q000188:drug therapy* / Q000556:secondary*; D005260:Female; D006801:Humans; D007094:Imides / Q000627:therapeutic use*; D007546:Isoquinolines / Q000627:therapeutic use*; D008875:Middle Aged; D053644:Naphthalimides; D063065:Organophosphonates; D010051:Ovarian Neoplasms / Q000188:drug therapy* / Q000473:pathology
D000970:Antineoplastic Agents; D007094:Imides; D007546:Isoquinolines; D053644:Naphthalimides; D063065:Organophosphonates; C037020:amonafide; D000225:Adenine